SparingVision Expands Novel Ocular Disease Pipeline with Acquisition of GAMUT Therapeutics

4BIO Capital’s review of AAV gene therapy clinical trials published in Nature Reviews Drug Discovery

4BIO Capital leads SparingVision’s €44.5 million financing round

4BIO Capital announces appointment of Professor Kenya Honda to Scientific Advisory Board

4BIO Capital appoints Brian P. McVeigh as Venture Partner

4BIO Capital announces strategic investment from Japanese pharmaceutical company Kyowa Kirin